Lalitha Podila

Variability in P-Glycoprotein Inhibitory Potency (IC50) Using Various in Vitro Experimental Systems: Implications for Universal Digoxin Drug-Drug Interaction Risk Assessment Decision Criteria

Joe Bentz, Michael O′Connor, Dallas Bednarczyk et al. · Drug Metabolism and Disposition · 2013 · 147 citations · Full text

FUNCTIONAL ASSESSMENT OF MULTIPLE P-GLYCOPROTEIN (P-GP) PROBE SUBSTRATES: INFLUENCE OF CELL LINE AND MODULATOR CONCENTRATION ON P-GP ACTIVITY

Mitchell E. Taub, Lalitha Podila, Diane Ely et al. · Drug Metabolism and Disposition · 2005 · 124 citations

Differential Selectivity of Efflux Transporter Inhibitors in Caco-2 and MDCK–MDR1 Monolayers: A Strategy to Assess the Interaction of a New Chemical Entity with P-gp, BCRP, and MRP2

Kirsten Mease, Rucha Sane, Lalitha Podila et al. · Journal of Pharmaceutical Sciences · 2012 · 73 citations

Molecular Pharmacology, Mdck–mdr1 Monolayers, Drug Target +11

Mechanisms Underlying Benign and Reversible Unconjugated Hyperbilirubinemia Observed with Faldaprevir Administration in Hepatitis C Virus Patients

Rucha Sane, Gerhard Steinmann, Qihong Huang et al. · Journal of Pharmacology and Experimental Therapeutics · 2014 · 34 citations

1236 MECHANISMS OF ISOLATED UNCONJUGATED HYPERBILIRUBINEMIA INDUCED BY THE HCV NS3/4A PROTEASE INHIBITOR BI201335

Rucha Sane, Lalitha Podila, Arvind Mathur et al. · Journal of Hepatology · 2011 · 18 citations · Full text

Molecular Pharmacology, Biochemistry, Medicine +5